Pembrolizumab

Generic Name
Pembrolizumab
Brand Names
Keytruda
Drug Type
Biotech
Chemical Formula
-
CAS Number
1374853-91-4
Unique Ingredient Identifier
DPT0O3T46P
Background

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...

Indication

Pembrolizumab is indicated for the following conditions:

For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.

Associated Conditions
Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Dai, Guanghai
Target Recruit Count
35
Registration Number
NCT06708858
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases

First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
Rakuten Medical, Inc.
Target Recruit Count
408
Registration Number
NCT06699212
Locations
🇺🇸

Cancer Clinic, Lexington, Kentucky, United States

A Clinical Study of MK-3475A to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

First Posted Date
2024-11-20
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
160
Registration Number
NCT06698042
Locations
🇬🇹

CELAN,S.A ( Site 1104), Guatemala, Guatemala

🇬🇹

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 1102), Guatemala, Guatemala

🇰🇷

Pusan National University Hospital ( Site 3002), Pusan Kwangyokshi, Pusan-Kwangyokshi, Korea, Republic of

and more 6 locations

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2024-11-18
Last Posted Date
2024-12-11
Lead Sponsor
AstraZeneca
Target Recruit Count
880
Registration Number
NCT06692738
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
Prelude Therapeutics
Target Recruit Count
60
Registration Number
NCT06682806
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

First Posted Date
2024-11-01
Last Posted Date
2024-11-01
Lead Sponsor
University of Chicago
Target Recruit Count
35
Registration Number
NCT06669572
Locations
🇺🇸

o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

First Posted Date
2024-10-28
Last Posted Date
2024-10-28
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1040
Registration Number
NCT06661720

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

First Posted Date
2024-10-16
Last Posted Date
2024-11-14
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
137
Registration Number
NCT06644768
Locations
🇺🇸

University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California, United States

🇺🇸

California Research Institute, Los Angeles, California, United States

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

and more 38 locations

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

First Posted Date
2024-10-15
Last Posted Date
2024-11-05
Lead Sponsor
Essen Biotech
Target Recruit Count
85
Registration Number
NCT06640582
Locations
🇨🇳

District One Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy